Xingjuan Jane Chao, Ph.D., serves as President, Chief Executive Officer, and Co-Founder of Ceribell Inc., a trailblazing medical technology company dedicated to transforming neurological diagnostics. Co-founding Ceribell in 2016, Dr. Chao has led the development and commercialization of the Ceribell System, an FDA-cleared point-of-care EEG platform that enables rapid seizure detection at the bedside. Under her stewardship, the company has achieved widespread adoption in over 500 U.S. hospitals, empowering clinicians to identify non-convulsive seizures—often missed in up to 30% of cases—and improve patient outcomes in critical care settings. With a Ph.D. in Electrical Engineering from Stanford University, Dr. Chao's academic research centered on neural signal processing and brain-machine interfaces. Her professional journey includes pivotal engineering leadership roles at NeuroPace, where she contributed to implantable devices for epilepsy treatment, and Intan Technologies, advancing high-density neural recording systems. These experiences honed her expertise in neurotechnology, bridging innovative research with practical clinical applications. Dr. Chao's achievements are marked by securing over $150 million in venture funding, multiple FDA clearances, and groundbreaking clinical studies demonstrating the Ceribell System's efficacy in reducing diagnostic times by up to 90%. A recognized leader in medtech, she has been honored with awards for innovation and continues to drive Ceribell's mission to make advanced EEG accessible, ultimately saving lives through faster, more precise neurological care.